One of the most common questions I receive in my vasculitis clinic is one of the most difficult to answer: “When can we stop rituximab?” While we know everyone needs therapy for at least one year and have reasonably good data for 18 months, whether folks should continue after that remains an open question. That is why I was especially excited to see a post hoc analysis of RITAZAREM, which followed patients for up to 48 months from enrollment

Consider holding methotrexate for two weeks after each recombinant zoster vaccine dose when disease is stable, and give the vaccine before rituximab when timing allows. Those are the messages from a pair of abstracts presented by Ana Cristina Medeiros-Ribeiro of the HC-FMUSP group in São Paulo at ACR Convergence 2026. One asks how long the response lasts on immunosuppression. The other asks whether it can be improved.